US FDA awards $72 million contract for Sentinel postmarketing surveillance
This article was originally published in Scrip
Executive Summary
The US FDA has finally made a bold move concerning the development of its Sentinel active postmarketing surveillance system, which the agency hopes, once operational, will allow it to query large electronic claims and medical records databases.